[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,056,030,720
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.51
  • Price/Sales 16.60
  • Price/Cash Flow 45.70
  • Price/Book 34.68

Options Overview Details

View History
  • Implied Volatility 45.78% (+1.53%)
  • Historical Volatility 34.48%
  • IV Percentile 97%
  • IV Rank 95.15%
  • IV High 46.75% on 04/15/26
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 3) 70.23 (6.31%)
  • Put/Call Vol Ratio 1.10
  • Today's Volume 47,472
  • Volume Avg (30-Day) 45,334
  • Put/Call OI Ratio 1.25
  • Today's Open Interest 335,973
  • Open Int (30-Day) 352,310
  • Expected Range 1,043.06 to 1,183.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.71
  • Number of Estimates 4
  • High Estimate $8.80
  • Low Estimate $5.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +6.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,109.15 +0.30%
on 08/03/26
1,249.45 -10.96%
on 07/07/26
-101.38 (-8.35%)
since 07/02/26
3-Month
943.26 +17.95%
on 05/11/26
1,249.45 -10.96%
on 07/07/26
+144.60 (+14.94%)
since 05/04/26
52-Week
623.78 +78.35%
on 08/08/25
1,249.45 -10.96%
on 07/07/26
+343.53 (+44.67%)
since 08/04/25

Most Recent Stories

More News
What To Expect From Eli Lilly’s (LLY) Q2 Earnings

What To Expect From Eli Lilly’s (LLY) Q2 Earnings

LLY : 1,119.45 (-0.17%)
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

INDIANAPOLIS , Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA)  has granted Breakthrough Therapy designation to...

LLY : 1,119.45 (-0.17%)
Stocks Set to Open Higher as Oil Sinks on U.S.-Iran Deal Hopes, Jobs Data and Earnings Awaited

September S&P 500 E-Mini futures (ESU26) are up +0.57%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.47% this morning, pointing to a higher open on Wall Street as oil prices sank after U.S....

GOOGL : 377.35 (+1.03%)
UAL : 132.64 (+3.31%)
AAPL : 309.70 (+2.07%)
SNDK : 1,442.87 (+12.02%)
NQU26 : 29,861.75 (+3.36%)
PFE : 25.40 (+1.48%)
SHOP : 122.85 (+4.99%)
MSFT : 492.62 (+1.02%)
TSLA : 327.48 (+1.68%)
FERG : 255.42 (+2.14%)
WDC : 550.91 (+4.49%)
ESU26 : 7,765.00 (+1.79%)
Jobs Numbers Set for Release Next Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...

SONY : 22.35 (-1.24%)
SNDK : 1,442.87 (+12.02%)
COP : 117.96 (-1.01%)
NVO : 44.39 (-5.73%)
CAT : 876.28 (+5.57%)
MRK : 128.06 (+0.23%)
VRTX : 478.82 (+1.72%)
AMD : 531.51 (+9.67%)
LLY : 1,119.45 (-0.17%)
PH : 992.16 (-0.54%)
PLTR : 161.79 (+28.76%)
MAR : 345.20 (-0.47%)
Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide...

APP : 419.50 (+3.28%)
ANET : 215.00 (+16.29%)
SPOT : 478.39 (-1.63%)
SNDK : 1,442.87 (+12.02%)
MRK : 128.06 (+0.23%)
PFE : 25.40 (+1.48%)
MCD : 268.31 (+1.16%)
DIS : 98.17 (+0.03%)
SHOP : 122.85 (+4.99%)
SPCX : 127.11 (+10.98%)
CAT : 876.28 (+5.57%)
AMD : 531.51 (+9.67%)
NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

NVO : 44.39 (-5.73%)
LLY : 1,119.45 (-0.17%)
3 Quality Compounders to Own for Decades

3 Quality Compounders to Own for Decades

FIX : 1,774.70 (+0.21%)
LLY : 1,119.45 (-0.17%)
DASH : 202.37 (+0.93%)
3 Divine Dividend-Growth ETFs

If you want to diversify your holdings across many dividend growers all at once, check out these dividend-growth ETFs.

MSFT : 492.62 (+1.02%)
LIN : 484.59 (+0.86%)
AVGO : 418.70 (+6.75%)
EFAD : 44.47 (+1.16%)
VIG : 243.88 (+1.55%)
XOM : 153.97 (-0.70%)
LLY : 1,119.45 (-0.17%)
WMT : 111.55 (+0.76%)
NOBL : 58.16 (+1.29%)
ED : 108.38 (+0.40%)
ASML : 1,710.39 (+4.13%)
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

LLY : 1,119.45 (-0.17%)
Lilly confirms date and conference call for second-quarter 2026 financial results announcement

INDIANAPOLIS , July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call...

LLY : 1,119.45 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,205.27
2nd Resistance Point 1,183.61
1st Resistance Point 1,152.48
Last Price 1,116.00
1st Support Level 1,099.69
2nd Support Level 1,078.03
3rd Support Level 1,046.90

See More

52-Week High 1,249.45
Last Price 1,116.00
Fibonacci 61.8% 1,010.44
Fibonacci 50% 936.61
Fibonacci 38.2% 862.79
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.